JAK抑制剂治疗难治性抗合成酶综合征:一项回顾性队列研究
该回顾性队列纳入2020年10月至2023年6月接受JAK抑制剂治疗的20例难治性抗合成酶综合征患者,全部合并间质性肺病。JAK抑制剂治疗后14例(70%)临床表现显著改善,关节炎、皮疹、气短、咳嗽、肌痛、肌无力比例均下降,CK、ESR、CRP、CT评分及糖皮质激素剂量降低。作者认为JAK抑制剂对多数难治性患者有效,但需更大规模前瞻性对照研究评估疗效。
要点
- 20例难治性抗合成酶综合征患者接受JAK抑制剂治疗,全部合并间质性肺病。
- 14例(70%)临床表现显著改善,关节炎、皮疹、气短、咳嗽、肌痛、肌无力比例均下降。
- CK、ESR、CRP、CT评分及糖皮质激素剂量显著降低。
核心结论
- JAK抑制剂对多数难治性抗合成酶综合征患者有效,表现为皮疹、肌炎和间质性肺病改善;但需更大规模前瞻性对照研究评估其疗效。
研究设计与样本
- 回顾性队列研究,回顾2020年10月至2023年6月接受JAK抑制剂治疗的所有难治性抗合成酶综合征患者病历,共纳入20例,全部(100%)合并间质性肺病。
主要发现
- JAK抑制剂治疗后14例(70%)难治性抗合成酶综合征患者临床表现显著改善。
- 关节炎比例从56.3%降至6.3%(p=0.002),皮疹从77.8%降至27.8%(p=0.012),气短从55.6%降至16.7%(p=0.039),咳嗽从61.1%降至11.1%(p=0.012)。
- 肌痛从50%降至11.1%(p=0.016),肌无力从61.1%降至11.1%(p=0.012)。
- 治疗前5例CK异常升高的患者CK水平显著降低(1096±1042.98 IU/L vs 199.2±144.66 IU/L,p=0.043)。
- ESR(p=0.001)和CRP(p=0.023)水平下降;抗合成酶综合征相关间质性肺病CT评分降低(188.75±69.67 vs 156.35±74.62,p=0.001);糖皮质激素剂量显著降低(21.42±13.26 mg vs 11.32±8.59 mg,p=0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文结论指出需更大规模前瞻性对照研究评估JAK抑制剂疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate the efficacy and safety of Janus kinase inhibitors (JAKi) in the treatment of refractory anti-synthetase syndrome (ASS) in real-world clinical settings. METHODS: The medical records of all refractory ASS patients who were treated with JAKi from October 2020 to June 2023 were retrospectively reviewed. RESULTS: Twenty patients were included, and all (100 %) patients had interstitial lung disease (ILD). After treatment with JAKi, 14 (70 %) of the refractory ASS patients showed significant improvement in clinical manifestations, including arthritis (56.3 % vs. 6.3 %, p = 0.002), rash (77.8 % vs. 27.8 %, p = 0.012), shortness of breath (55.6 % vs. 16.7 %, p = 0.039), cough (61.1 % vs. 11.1 %, p = 0.012). Improvement was noted for myalgia (50 % vs. 11.1 %, p = 0.016) and muscular weakness (61.1 % vs. 11.1 %, p = 0.012), while creatine kinase (CK) levels, which were abnormally elevated in five patients prior treatment, were significantly lowered (1096 ± 1042.98 IU/L vs. 199.2 ± 144.66 IU/L, p = 0.043). A decrease in levels of inflammatory markers, including erythrocyte sedimentation rate (ESR) (p = 0.001) and C-reactive protein (CRP) (p = 0.023) was observed in the patients. In ASS-ILD, the CT score reduced (188.75 ± 69.67 vs. 156.35 ± 74.62, p = 0.001). Furthermore, the glucocorticoid dose significantly reduced (21.42 ± 13.26 mg vs. 11.32 ± 8.59 mg; p = 0.001). CONCLUSIONS: JAKi were effective in most refractory ASS patients as evidenced by improved skin rash, myositis, and ILD. However, larger prospective controlled studies are required to evaluate its efficacy.
引用
- Shan X, Wu S, Chen X, et al. Janus kinase inhibition (JAKi) therapy in refractory anti-synthetase syndrome: A retrospective cohort study. Semin Arthritis Rheum. 2024. PMID: 38857549. doi:10.1016/j.semarthrit.2024.152474
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。